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Aims: In many physiologic systems, the evolution from health to disease correlates with a loss 
of complexity in the system’s output. We analyze the difference in complexity of the glycemic 
proﬁ  le in healthy volunteers (H), patients with the metabolic syndrome (MS), and patients with 
type 2 diabetes mellitus (DM).
Methods: We measured interstitial ﬂ  uid glucose every 5 minutes for 3 days in 10 H, 10 MS, 
and 10 DM. Complexity of the glycemic proﬁ  le was evaluated by means of detrended ﬂ  uctuation 
analysis (DFA). Mean amplitude of glycemic excursions (MAGE) was also calculated.
Results: Glucose proﬁ  le was more complex (lower DFA) in healthy subjects than in patients 
with MS or DM (mean DFA [SD]: H: 1.25 (0.10), MS: 1.39 (0.07), DM: 1.42 (0.10). ANOVA: 
F2,27 = 9.94, p = 0.001). DM had also a less complex proﬁ  le than MS, but this difference was 
not statistically signiﬁ  cant. There was an inverse relation between complexity (lower DFA) 
and the number of MS deﬁ  ning criteria (rho = 0.55, p = 0.002) and between complexity and 
MAGE (r = 0.68, p   0.0001).
Conclusions: There is a progressive loss of complexity in the glycemic proﬁ  le from health, 
through the metabolic syndrome to type 2 diabetes mellitus. This loss of complexity precedes 
hyperglycemia and correlates with other markers of disease progression. Complexity analysis 
may be a useful tool to track the evolution from health to type 2 diabetes. Furthermore, it may 
provide a way to measure glycemic control in real-life situations and has some distinct advantages 
over other conventional variability metrics.
Keywords: complexity, metabolic syndrome, type 2 diabetes mellitus, detrended ﬂ  uctuation 
analysis, glycemic proﬁ  le
Introduction
Type 2 diabetes mellitus (DM) affects about 5% of adults worldwide, and this 
prevalence is rising rapidly (Secree and Zimmet 2003). Individuals with impaired 
fasting glucose (IFG) or impaired glucose tolerance are asymptomatic but are at high 
risk of future type 2 diabetes and vascular disease (Unwin et al 2002). Nevertheless, 
these deﬁ  nitions of prediabetes have limitations and even the current cut-off levels 
proposed by the American Diabetes Association for IFG (fasting plasma glucose 
 100 mg/dl) are open to debate (Cheng et al 2006; Andreozzi et al 2007; Nichols 
et al 2007; Rijkelijkhuizen et al 2007).
During the past few years, the term “metabolic syndrome” (MS) has been 
increasingly used in medical literature. It describes the clustering in an individual of 
several traits, including insulin resistance, obesity, hypertension, and dyslipidemia, 
which are all highly prevalent in the Western lifestyle and each represent a major risk 
factor for cardiovascular disease (WHO 1999; NCEP 2002). Several recent reports 
show that the metabolic syndrome is associated with a large increase in the risk Diabetes, Metabolic Syndrome and Obesity 2008:1 4
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of cardiovascular events (Lakka et al 2002; Girman et al 
2004) and several pieces of evidences suggest a common 
pathophysiological background for this syndrome, at the 
center of which lies insulin resistance (Zimmet 1992). 
Patients with the MS are also at increased risk of developing 
DM (Hanley et al 2004).
The MS is very prevalent in developed countries (Ford 
and Giles 2003; Park et al 2003). The increasing burden 
of obesity worldwide is the driving force behind the rising 
prevalence of the DM and MS (Park et al 2003; Carr 
et al 2004).
The progress from normal health through the MS to 
overt DM is arguably a gradual evolution, and its division 
into distinct steps is probably artiﬁ  cial. A smoother, more 
quantitative approach may provide a better description of this 
evolution. Unfortunately, the hallmark of this progress, insulin 
resistance, is not easy to measure in real-life conditions. We 
intend to ascertain whether complexity analysis may provide 
a new tool to describe this process.
Complex biological systems are characterized by a highly 
elaborate output. Often, one of the ﬁ  rst symptoms of disease 
is a “decomplexiﬁ  cation” of this output, due to uncoupling 
or loss of its processing capacities (Goldberger 1997; 
Goldberger et al 2002). Complexity analysis techniques 
may provide an easy and sensitive way of displaying this 
phenomenon (Varela et al 2005, 2006).
This is probably the case in the evolution from health 
through MS until DM. Namely, we suggest that the 
derangement of glucose metabolism that underlies this 
evolution is displayed as a gradual and progressive loss of 
complexity in the glycemic time series as each patient walks 
his way from normality to full-blown DM.
We intend to develop an instrument that may give some 
quantitative insight into the evolution from the normal, 
healthy state through the MS to DM, in real-life conditions. 
We correlate this tool with a classic measure of variability: 
the mean amplitude of glycemic excursions (MAGE). This 
metric has been used to assess acute glucose ﬂ  uctuations and 
was found to be related with activation of oxidative stress 
markers in DM (Monnier et al 2006).
Patients and methods
Ten successive patients with the MS (deﬁ  ned by National 
Cholesterol Education Program – Adult Treatment Panel 
III (NCEP-ATPIII) criteria (Secree and Zimmet 2003), 
excluding type 2 diabetes) and 10 successive patients with 
DM (deﬁ  ned as fasting plasma glucose  126 mg/dl in two 
consecutive occasions and/or on antidiabetic treatment) were 
selected from the outpatient internal medicine and vascular 
risk clinics of a urban 400-bed teaching hospital in Madrid, 
Spain. Only patients with a recent diagnosis of DM (less than 
one year), and only on dietary or oral antidiabetic treatment 
were selected. 10 healthy volunteers were used as controls. 
To avert the inﬂ  uence of gender and hormonal status, only 
men were selected. We intentionally chose early DM to high-
light the possible differences in these ﬁ  rst stages of DM. The 
study was approved by the Hospital's Ethics Committee, and 
an informed consent was obtained from each patient.
The characteristics of patients and controls are displayed 
in Table 1.
On admission to the study, after a full clinic exam, blood 
was extracted to measure basic biochemical parameters 
(including fasting plasma glucose, glycosylated hemoglobin, 
insulin, and lipids). Then a sensor was inserted in the 
abdominal subcutaneous tissue, and interstitial glucose was 
recorded every 5 minutes for at least 48 hours (CGMS System 
Gold, Medtronic MiniMed, Medtronic Diabetes, Northridge, 
CA, USA). Subjects were asked to record at least 3 ﬁ  ngerstick 
measurements daily. Otherwise, patients carried on with their 
normal ambulatory life, followed their normal treatment, and 
were not required to take any special care.
A glucose time series was obtained from each subject. 
From this series, we extracted a 24-hour long series (from 
06.00 AM on day 2 to 06.00 AM on day 3) for study. We 
selected day 2 to avert the stressing inﬂ  uences of insertion 
and laboratory exams, and we excluded day 4 because of 
the concern of claudication of the capillary probe. Figure 1 
shows an example of a healthy subject, a patient with the 
MS, and a patient with DM.
Conventional statistics (mean or median, standard 
deviation [SD], or interquartile range) were recorded from 
the time series. MAGE was calculated according to Service 
and colleagues (1987).
Complexity analysis
The complexity of the glucose proﬁ  le was evaluated by 
means of detrended ﬂ  uctuation analysis (DFA). DFA is a well 
established technique to measure the complexity of a time 
series. An in-depth discussion on DFA is outside the scope of 
this paper, and may be seen in Peng and colleagues (2000). 
A summary is presented in the Appendix. Very schematically, 
DFA analyses how a time series and its linear regression 
diverge as the “time window” increases. Intuitively, DFA 
can be conceived as representing the span of inﬂ  uence of 
the different points in a time series. In a series with high 
complexity, the inﬂ  uence of each point rapidly fades away, Diabetes, Metabolic Syndrome and Obesity 2008:1 5
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while in a “smoother” series the inﬂ  uence of each point lasts 
longer. As a rule of thumb, higher complexities are displayed 
as lower DFA (until a minimum of 0.5).
Statistics
Differences among groups were evaluated by means of 
ANOVA, with post-hoc analysis (Tukey) when necessary. 
Univariate ANOVA was used to correct for other covariables. 
When normality conditions were not fulﬁ  lled, Kruskal-Wallis 
test was employed.
Spearman correlation was used to analyze the relation 
between complexity and the number of metabolic syndrome-
deﬁ  ning criteria.
Linear regression was used to correlate DFA and 
MAGE.
In every case, statistical signiﬁ  cance was assumed if 
p   0.05. The statistical software employed was SPSS 
version 12 (SPSS Inc., Chicago, IL, USA).
Results
The patient’s characteristics are displayed in Table 1. The 
glucose proﬁ  le was clearly more complex (ie, lower DFA) in 
healthy subjects than in patients with the metabolic syndrome 
or in diabetic patients (mean DFA [SD] in healthy controls: 
1.25 (0.10), MS: 1.39 (0.07), DM 1.42 (0.10); ANOVA: 
F2,27 = 9.94, p = 0.001). In the post-hoc analysis, healthy 
subjects differed both from patients with the MS (p = 0.006) 
and with DM (p = 0.001). Diabetic patients had also a less 
complex proﬁ  le than patients with the metabolic syndrome, 
but this difference did not achieve statistical signiﬁ  cance 
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A: Healthy subject
mean glucose: 83mg/dl
sd: 6 mg/dl
DFA*: 1.17
MAGE†: 13.5
B: Metabolic syndrome
mean glucose: 92 mg/dl
sd: 9 mg/dl
DFA: 1.40
MAGE: 30
C: Type 2 diabetes
mean glucose: 112 mg/dl
sd: 25 mg/dl
DFA: 1.53
MAGE: 68
Figure 1 Example of a glycemic proﬁ  le of a patient of each group.
Notes: *DFA, detrended ﬂ  uctuation analysis; †MAGE, mean amplitude of glycemic excursions.Diabetes, Metabolic Syndrome and Obesity 2008:1 6
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(Figure 2). This results did not change signiﬁ  cantly when 
corrected for the effect of age (ANOVA F2,26 = 8.72, 
p = 0.002), body mass index (F2,26 = 8.06, p = 0.002), waist 
circumference (F2,26 = 7.85, p = 0.002), or fasting plasma 
glucose (F2,26 = 4.90, p = 0.016). Also, correcting for systolic 
or diastolic blood pressure, total cholesterol, high-density 
lipoprotein-cholesterol, low-density lipoprotein-cholesterol, 
or triglycerides did not change signiﬁ  cantly these results 
(F   7.80, p   0.002 in every case). If the whole time series 
recorded was analyzed (in stead of just the second day), the 
results were similar (DFA in healthy controls:1.26 [SD 0.05]; 
MS:1.36 [SD 0.05]; DM:1.42 [SD 0.07]).
There was a statistically signiﬁ  cant inverse relation 
between profile complexity and the number of meta-
bolic syndrome deﬁ  ning criteria (NCEP-ATPIII criteria 
[Secree and Zimmet 2003] (rho = 0.55, p = 0.002). These 
results did not differ if patients with full blown DM were 
excluded (rho = 0.58, p = 0.008), nor when adjusted for age 
(rho = 0.55, p = 0.002).
By way of contrast, variability, as measured through 
MAGE, increased from health (30.0 [SD 14.3]) to MS (45.5 
[17.2]) and DM (62.7 [27.5]). With ANOVA, the post-hoc 
analysis could differentiate between healthy subjects and 
diabetic patients, but it could not discriminate between healthy 
subjects and MS or between MS and DM. These results did not 
change signiﬁ  cantly when correcting for age, body mass index, 
or waist circumference, but when correcting for fasting glucose, 
MAGE became nonsigniﬁ  cant (F2,26 = 0.551, p = 0.58).
A highly signiﬁ  cant correlation was observed between 
DFA and MAGE (r = 0.68, p   0.0001): high variability corre-
lated with high DFA (and thus, low complexity) (Figure 3).
Discussion
The evolution from health to DM seems to be marked by 
a progressive loss of complexity in the glycemic proﬁ  le, 
probably reﬂ  ecting increasing insulin resistance and a failing 
glucoregulation. This loss of complexity appears well before 
the development of hyperglycemia. Overall, our MS patients 
had a fasting plasma glucose lower than 110 mg/dl, and 40% 
of them less than 100 mg/dl.
We did not ﬁ  nd signiﬁ  cant differences in the glycemic 
proﬁ  le complexity in MS patients when compared with DM. 
However, the signiﬁ  cant inverse correlation between the 
complexity of the glycemic proﬁ  le and the number of MS 
criteria in each patient suggests that the path from health 
through the MS to DM is more a quantitative than a qualitative 
change, and highlights the fuzziness of their limits.
Blood glucose variability has recently emerged as 
an important variable in critical care both in diabetic 
and nondiabetic patients (Egi et al 2006), as well as an 
Table 1 Patient’s characteristics
Healthy controls 
(H)
Metabolic syndrome 
(MS)
Type 2 diabetes 
(DM)
Age (yr) 45.2 (17.3) 50.7 (11.9) 59.7 (7.2) F2,27* = 4.08, p = 0.028 H-DM p = 0.022
BMI (Kg/m2) 26.2 (3.0) 33.3 (4.9) 29.8 (5.8) F2,27* = 5.49, p = 0.010 H-MS p = 0.007
Waist (cm) 94 (16.4) 112.4 (13.6) 107.2 (11.6) F2,27* = 5.34, p = 0.011 nsd
Systolic BP (mm Hg) 142 (28.1) 148 (20.6) 144 (25.1) nsd
Diastolic BP (mm Hg) 83 (9.3) 90 (13.4) 83 (11.7) nsd
Glucose (mmol/L) 5.46 (0.40) 5.97 (0.69) 7.47 (1.31) F2,27* = 14.37, p   0.001 H-DM p = 0.001; MS-DM 
p = 0.002
HDL-C (mmol/l) 1.33 (0.21) 1.19 (0.21) 1.39 (0.39) nsd
Triglycerides (mmol/L) 1.11 (0.37) 1.50 (0.61) 1.49 (0.68) nsd
Glycosylated Hb (%) 5.3 (0.5) 5.9 (0.3) 6.8 (1.1) F2,27* = 10.68, p   0.001 H-DM p = 0.001; MS-DM 
p = 0.030
Insulin (pmol/L) 51 (16) 107 (83) 101 (77) KW nsd
HOMA-IR 2.1 (0.7) 4.6 (3.2) 5.6 (4.5) KW† Chi2 = 8.43, 
p = 0.015
DFA 1.39 (0.10) 1.39 (0.07) 1.42 (0.10) F2,27* = 9.94, p = 0.001 H-DM p = 0.001; MS-DM 
p = 0.006
MAGE 30.0 (14.3) 45.5 (17.2) 62.7 (27.5) F2,27* = 6.38, p = 0.005 H-DM p = 0.004
Abbreviations: BMI, body mass index; BP, blood pressure; DFA, detrended ﬂ  uctuation analysis; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, Homeostatic Assessment 
Model of Insulin Resistance; MAGE, mean amplitude of glycemic excursions.
Notes: *ANOVA, †Kruskal-Wallis.
Units conversion: Glucose (mg/dl) = Glucose (mmol/L) * 18.02; HDL-C (mg/dl) = HDL-C (mmol/L) * 38.61; Triglycerides (mg/dl) = Triglycerides (mmol/L) * 88.50; Insulin 
(uU/ml) = Insulin (pmol/L) * 0.1667.Diabetes, Metabolic Syndrome and Obesity 2008:1 7
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independent risk factor for diabetic complications in DM 
(Saudek et al 2006). We found a tight inverse correlation 
between glycemic variability (measured with MAGE) and 
complexity (measured with DFA). It would seem as if all 
through the evolution from health to full-blown DM, the 
glucoregulatory system became progressively more “sloppy” 
and slow-reacting, and required bigger departs from baseline 
to launch a counteregulatory response. Thus, although the 
coincidence of increased variability and loss of complexity 
may at ﬁ  rst glance seem contradictory, it probably represents 
Figure 2 Differences in detrended ﬂ  uctuation analysis among healthy subjects, patients with the metabolic syndrome and patients with type 2 diabetes.
Figure 3 Correlation between detrended ﬂ  uctuation analysis and mean amplitude of glycemic excursions.
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just two different aspects of the same disorder, namely, the 
loss of ﬁ  ne regulation on glycemic levels.
Complexity measures may have some advantages over 
classic MAGE. In the ﬁ  rst place, it is less operator-dependent. 
In order to measure MAGE, each peak has to be assessed as 
to decide whether it qualiﬁ  es as an excursion. Furthermore, 
the qualifying limit (usually, 1 SD) is arbitrary, and minor 
imprecisions on this measure have substantial consequences 
on the results. Finally, the discriminant power of MAGE 
depends heavily on plasma glucose, and correcting for this 
variable invalidates its diagnostic capacity.
By way of contrast, DFA is not operator-dependent 
and does not depend on an arbitrary limit. Furthermore, it 
explores the glucoregulatory response throughout the whole 
time series, thereby analyzing all the span of glycemic 
variations and not just the biggest ones.
It could be argued that the loss of complexity observed 
in MS and DM may be an artifact due to differences in body 
composition. Both groups have higher body mass index and 
probably their subcutaneous tissue will have an increase 
adiposity that could inﬂ  uence the sampling of interstitial 
ﬂ  uid. Nevertheless, adjusting for body mass index or waist 
circumference does not signiﬁ  cantly change the results.
Recently, Ogata and colleagues (2006, 2007) analyzed 
diabetes-related alterations of glucose control by means of 
DFA on a continuous glucose monitoring system. Their 
results on healthy volunteers (DFA 1.25 [SD 0.29]) are 
almost identical to ours. DFA in diabetic patients is slightly 
higher in their series (DFA 1.65 [0.30] vs 1.42 [0.10]), 
probably reﬂ  ecting more advanced diabetes. These authors 
propose that the break down of the physiologic negative 
long-range correlation in glycemia observed in patients with 
diabetes proves that the net effects of the ﬂ  ux and reﬂ  ux 
persist for many hours and may reﬂ  ect a central pathogenic 
mechanism in diabetes, ie, the lack of tight control in blood 
glucose. These observations support our hypothesis that new 
metrics derived from complexity analysis could improve 
diagnostic and prognostic work-up in diabetes, and help in 
the understanding of glucose dysregulation in this disease.
An objection that can be raised is that subjects did not 
follow a standardized life regime, and variation on meals or 
activity may confound our results. Nevertheless, we tried to 
develop a real-life model, displaying what happens in normal 
life, easy to apply in daily practice, rather than a research 
instrument.
Also, it could be argued that glucose levels in interstitial 
ﬂ  uid may not accurately reﬂ  ect plasma levels, and that our 
results may show differences in the plasma/interstitium 
kinetics rather than in plasmatic values. Obviously, this 
caveat would also apply to other routine uses of CGMS (ie, 
insulin dose adjustment, insulin infusion pumps, etc) that 
don’t consider these limitations.
In conclusion, if corroborated, complexity analysis of 
the glycemic proﬁ  le may provide a useful technique to 
track the evolution from health through the MS to DM in 
real-life conditions. Glucose instability and its contribution 
to diabetic cardiovascular risk could also be assessed in this 
way. Furthermore, complexity analysis may be helpful in the 
evaluation of the new “insulin-sensitizing” drugs and their 
possible contribution in improving glucoregulation.
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Appendix
Detrended ﬂ  uctuation analysis
Detrended ﬂ  uctuation analysis (DFA) attempts to disclose 
patterns of self-similarity in time plots. That is, it looks for 
the presence of “memory” in the curve; memory understood 
as long-range correlations.
In order to be able to perform DFA, it is ﬁ  rst necessary 
to integrate the time series:
  yk
i
k
() =
= ∑ 1(Gi − Gmean) (Figure  4)
where Gi is each individual point and Gmean is the mean of 
the series as a whole.
Next, the integrated curve is divided into time segments 
of size n (Figure 5A, B, C). A regression line is calculated 
for each segment, and the difference between the integrated 
curve and the different regression lines is computed:
F(n) = 
1 2
1 N
yk y k n
k
N
() () − []
= ∑
where F(n) is the measure of the difference between the 
integrated curve and the regression lines, N is the total 
number of data points, y(k) is the value of the integrated 
curve at each point, and yn(k) is the value of the regression 
line at that point.
This operation is repeated for different time frames (that 
is, for different values of n). The smaller the time scale (n), 
the better the ﬁ  t of the regression lines to the integrated curve, 
and the lower the value of F(n). Conversely, the value of 
F(n) tends to increase exponentially as the time frame (n) 
increases.
Finally, the relation between F(n) and the size of n is 
analyzed. A plot is drawn with log[F(n)] on the y-axis and 
log(n) on the x-axis (Figure 5D). A good ﬁ  t to a regression 
line indicates the existence of scaling (self-similarity), and 
a fractal structure can be assumed.
DFA is the slope of the regression line (α). It displays the 
scaling exponent, and is an indicator of the degree of complexity 
of the curve. In an entirely random time series (“white noise”) 
α = 0.5. A 1/f type time series will have α = 1. A “random 
walk” (the integration of a random series, “Brown noise”) will 
display α = 1.5. Long range negatively correlated ﬂ  uctuations 
will show α   1.5, while in positive correlations α  1.5.
On the whole, a curve is more complex (less predict-
able) the closer its value of α is to 0.5. (Values of α 
Figure 4 Detrended ﬂ  uctuation analysis (1). From the original time series, an integrated curve is obtained:
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Notes: Gi, each individual point; Gmean, mean of the series as a whole.   This integrated curve will be utilized for further calculations.
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Loss of complexity in the glycemic proﬁ  le
lower than 0.5 reveal anticorrelations, which also implies 
a certain degree of predictability, and hence a lower level 
of complexity).
In our series, N = 288.
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Figure 5 Detrended ﬂ  uctuation analysis (DFA) (2).   The integrated curve is divided into progressively smaller time segments (A, B, C, etc).  A regression line is calculated for each 
segment, and the total difference between the integrated curve and the regression lines is calculated for each time window (F(n), gray area). The smaller the time window, the 
better the ﬁ  t of the regression line and the lower the value of F(n). Finally, a plot is drawn (D) with log(F(n)) in the y-axis and log(time-window) in the x-axis.   A good ﬁ  t reveals 
the presence of scaling (self-similarity). DFA is the slope of the regression line. It displays the scaling exponent, and is an indicator of the degree of complexity of the curve.
The program used to calculate DFA was written in Python 
(http://www.python.org) and is available from the authors 
on request (mvarela.html@salud.madrid.org).